SION - Sionna Therapeutics, Inc. Operating profit EBITDA
Actual operating profit helps illustrate the strategy of Sionna Therapeutics Inc (SION) to automate small molecule screening via AI to combat cystic fibrosis. Precision robots accelerate preclinical testing, and 0.00 represents the current value of this metric. Since treating genetic pathologies is vital, the business remains independent of economic cycles, relying exclusively on patents and medical breakthroughs.
sionnatx.com (SION) - metric breakdowns and financial figures
- share price and expert price forecast:
- market capitalization statistics:
- book value of equity indicators:
- company total debt and liquidity indicators:
All Debt to Shareholders' Equity Ratio Sionna Therapeutics Inc|SION - Long-Term Debt to Capital|Current Liabilities to Capital Sionna Corp|SION - Company Debts|Debt to Net Assets Ratio Sionna Therapeutics Inc|SION - Company Long-Term Debts|Company Short-Term Debts Sionna Therapeutics|Critical Liquidity Ratio sionnatx.com
- earnings and market ratios statistics:
SION - Net Profit|Expected Net Profit Sionna Therapeutics Inc|SION - Price to Earnings Ratio|Forward P/E Multiple Sionna Pharma|SION - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Sionna Therapeutics Inc|SION - Operating profit EBITDA|Net earnings per share for the last four quarters Sionna Therapeutics|SION - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months sionnatx.com|SION - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Sionna Therapeutics Inc
- sales and revenue indicators:
Analysis of all company metrics:Sionna Therapeutics Inc
The complex logistics of cryogenic biomaterial transport require significant operating expenses for Sionna Therapeutics Inc (SION). This metric measures net profit from core operations, excluding the impact of the tax burden and debt obligations. This allows for an assessment of real cash flow generation efficiency without considering financial leverage. A decline in this metric signals capital dilution and an increase in hidden costs. By analyzing the current EBITDA level, an investor determines the fundamental stability of the business.
Who Sionna Therapeutics Inc competes with
Operating income before deduction of amortization Tempus AI Inc (TEM)|QGEN - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization IONS (Ionis Pharmaceuticals, Inc.)|RGEN: Operating profit EBITDA|Avidity - Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization CRSP|Profit before interest, taxes and amortization genedx.com WGS|Operating profit before deduction of amortization RARE (Ultragenyx Corp)|BEAM (Beam Therapeutics) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA SRPT (Sarepta Therapeutics Inc)|Operating income before deduction of amortization Twist Bio (TWST)|TXG: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization NTLA (Intellia Therapeutics)|Stoke Therapeutics (STOK) - Profit before payment of interest, taxes and amortization|BioLife Corp (BLFS) - Operating profit EBITDA|WVE (wavelifesciences.com) - Operating profit EBITDA|Operating profit EBITDA Maze Therapeutics Inc|Operating profit EBITDA PRME|TSHA (Taysha Gene Therapies) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization uniQure QURE|MGTX: Operating profit before amortization|REGENXBIO Inc - Operating profit EBITDA|Profit before interest, taxes and amortization Solid Corp|Ocugen (OCGN) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization Pacific Biosciences|Operating profit before deduction of amortization BNTC|Operating profit before deduction of amortization Design Therapeutics Inc (DSGN)|Operating profit EBITDA RCKT|Operating profit EBITDA 4D Molecular Therapeutics, Inc. (FDMT)|lexeotx.com - Operating profit before deduction of amortization|KRRO: Operating profit before amortization|Editas Corp - Operating profit EBITDA|SLN: Profit before payment of interest, taxes and amortization|PRQR (ProQR) - Operating profit before deduction of amortization|Operating profit before amortization CDXS|Profit before payment of interest, taxes and amortization sangamo.com|Operating profit before amortization NAUT (Nautilus Biotechnology)|Operating profit EBITDA MGX|Operating income before deduction of amortization Precision BioSciences Inc.|Operating profit EBITDA GBIO (Generation Bio Co)|Operating profit EBITDA Boundless Bio, Inc BOLD|Exicure Corp - Operating profit EBITDA|Operating income before deduction of amortization Imunon IMNN|PHIO: Operating profit EBITDA|MBIO: Company profit before taxes, interest and amortization|Profit before payment of interest, taxes and amortization TransCode Therapeutics, Inc.|Operating profit EBITDA Bionano Genomics, Inc.|Profit before payment of interest, taxes and amortization Applied DNA (APDN)|Profit before payment of interest, taxes and amortization BLUE (bluebird bio, Inc.)|Operating profit EBITDA IPA (immunoprecise.com)|Operating profit EBITDA Omega OMGA|OMIC - Profit before payment of interest, taxes and amortization|RGLS - Operating profit EBITDA|Syros Pharmaceuticals Inc. (SYRS) - Profit before payment of interest, taxes and amortization|TBIO (Telesis Bio, Inc.) - Profit before payment of interest, taxes and amortization|TCON (TRACON Pharmaceuticals Inc.) - Operating profit EBITDA|Profit before interest, taxes and amortization Unity Bio UBX
